New vaccine aims to boost immunity against advanced cervical cancer
NCT ID NCT06315257
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study is testing a new vaccine called PVX7 in 32 women with advanced cervical cancer who have finished their main treatment (surgery, radiation, or chemo). The goal is to see if the vaccine is safe and can boost the body's immune response against HPV, the virus that causes cervical cancer. Participants will receive three doses of the vaccine, and researchers will monitor side effects and immune system activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Email: •••••@•••••
-
The University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment